California Legalization Initiative Secures Spot on November Ballot

California will decide on legalizing marijuana for recreational use in November, after the Secretary of State’s office confirmed supporters submitted more than enough signatures for a ballot initiative, according to a Reuters report.

“Today marks a fresh start for California, as we prepare to replace the costly, harmful and ineffective system of prohibition with a safe, legal and responsible adult-use marijuana system that gets it right and completely pays for itself,” Jason Kinney, initiative spokesman, said in a statement.

The “Adult Use of Marijuana Act” would allow individuals 21-and-older to possess up to an ounce of cannabis for personal use and allow personal cultivation of up to six plants. Under the proposal, localities would decide whether or not to allow retail operations, which would be taxed. The Bureau of Marijuana Control would be created within the Department of Consumer Affairs to regulate the industry.

The measure needed more than 402,000 signatures and Secretary of State Alex Padilla is expected to certify the signatures today.

Voters defeated a similar measure in 2010 but, according to a May poll by the Public Policy Institute of California, 60 percent of voters in the state support a regulated marijuana industry. This measure has drawn the support of Lt. Gov. Gavin Newsom and billionaire Sean Parker.

End


Washington Medical Cannabis Database May Not Be Ready by July 1

Washington medical cannabis patients and providers should be prepared for delays in the roll-out of the state’s new medical regulations.

In particular, the state-managed database of medical cannabis authorizations is not ready yet, according to an email issued yesterday afternoon by the Washington Department of Health. This could spell dire consequences for Washington cannabis patients.

Lawmakers voted last summer to dismantle the state’s 18-year-old medical cannabis industry, and those regulations  — which assimilate the medical industry into the I-502 recreational market — are supposed to take effect this Friday, July 1. Under the new regulations, patients will be required to get medicine from licensed cannabis retail outlets.

Recreational retailers, however, charge significantly more for cannabis products than dispensaries and collectives charged in the medical industry.

Regulators had planned a database that patients would register with to receive patient recognition cards. With such a card, patients would be allowed to:

  • Purchase cannabis products sales-tax free.
  • Purchase up to three times the legal limit for recreational users.
  • Purchase products infused with higher amounts of THC than recreational users.
  • Grow more than four plants at home.
  • Enjoy full protection from arrest, prosecution, and legal penalties associated with their marijuana activities — though patients will still have an affirmative defense.

If the database is indeed delayed, it will inevitably spell trouble for Washington cannabis patients.

According to the Health Department’s email: “Patients and providers can still purchase marijuana from authorized retail stores; however, they can’t take advantage of the benefits until the database is operational.”

“The department is committed to ensuring patient safety, and it will continue to work on having the database ready as soon as possible,” the department said in its release.

Activists are planning a downtown Seattle protest for tomorrow during the afternoon rush hour to bring attention to the plight of Washington’s medical cannabis patients.

 

End


Seattle Protest Planned for June 30 Against Washington’s MMJ Shutdown

The NORML Women of Washington are organizing a protest in Seattle this Thursday, June 30, that aims to bring attention to the unfortunate criminalization of Washington’s robust, 18-year-old medical cannabis industry.

Starting Friday, July 1, medical cannabis patients and caregivers who have not assimilated into Washington state’s hyperregulated and exclusive recreational marijuana marketplace will become criminal, as per the Cannabis Patient Protection Act (SB 5052) passed by Washington lawmakers and signed by Gov. Jay Inslee last summer. For months, long-established dispensaries and community caregivers have been closing up shop — or going underground to the “informal” market — in preparation for the dramatic market shift, leaving many patients without adequate access to their medicine.

“While moving to a regulated system is understandably an imperfect journey, this date is significant because it will make people criminals that Washingtonians have voted to protect and have overwhelmingly supported for nearly two decades,” write the protest organizers on the event’s Facebook page. “This is NOT an anti-502 protest. We support the legalization of adult use marijuana and want to send a message to our representatives and regulators that patients and their caregivers need to be protected during this revolutionary process.”

The protest is scheduled for 4:00 p.m. to 7:00 p.m. on Thursday afternoon and protesters will be gathering on sidewalks at the corner of 6th Ave. and Union Street in Downtown Seattle — one of the busiest places in the city, during some of its busiest hours.

End


D.C. Health Department Backs Retail Cannabis System

Washington D.C.’s Department of Health is recommending taxing marijuana in the District, similar to regulatory models for alcohol and tobacco, according to a report issued by the department.

Initiative 71, D.C.’s legalization legislation, passed in February 2015 but so far no infrastructure has been set up for sales. District residents can possess, grow and give away for cannabis for recreational use, but there are no retail locations. 

Projections from ArcView Market Research and New Frontier estimate the legalized marijuana market in D.C. could be worth $93.6 million by 2020, DCist reported in March. Two years ago, Dr. Yesim Sayin Taylor, an official for the Office of the D.C. Chief Financial Officer, estimated the market could be worth $130 million a year assuming that 122,000 people would buy three ounces of cannabis a year at $350 an ounce.

In their report, the Health Department recommended using some of the funds gained from a comprehensive retail system to strengthen drug treatment and education programs, monitoring tobacco and alcohol use for cannabis users and non-users, and providing information to expecting mothers about the risks of marijuana use while pregnant and breast-feeding.

Kaitlyn Bocker, a policy analyst with the Drug Policy Alliance, is urging D.C. officials to move forward with the Health Department’s proposals “immediately.”

“As DOH’s recommendation recognizes, a regulatory system will increase public health and safety, allow our policy makers to address much needed reforms, and generate tax revenue to fund treatment and education,” she said in a DCist report.

End


Cannabis branches hanging out to cure after harvest season.

Cannabis Dispensaries Earn More Per Square Foot than Whole Foods

The average medical and/or recreational cannabis dispensary in the U.S. earns more money per square foot than the premium grocery store chain Whole Foods, according to the 2016 Marijuana Business Factbook.

Cannabis retailers have the advantage of dispensing a generally small-sized but expensive commodity, meaning that smaller storefronts can more easily generate the revenue per square foot of larger establishments. However, though the cannabis industry continues to enjoy rapid growth, it faces a wide host of problems ranging from archaic political stigmas to overreaching regulatory restrictions. Banking access in particular remains one of the industry’s most problematic issues, and, until that controversy is solved, cannabis retailers — in part because of the industry’s successful reputation — will remain at heightened risks of robbery and theft.

On average, cannabis dispensaries in 2015 earned $974 in annual revenue per square foot, about five percent more than Whole Foods’ $930 per square foot. On a whole, the cannabis industry earned between $3-4 billion in 2015.

Legalized cannabis isn’t completely edging out the premium grocery chain business, however: Costco stores pull in on average $1,032 per square foot, and the cannabis industry’s total revenue still pales in comparison to Whole Foods’ 2015 earnings of $15 billion. But, with medical marijuana legalized in half the U.S. states and recreational legalization votes coming up in nearly a half-dozen others, cannabis will likely be earning tens of billions of dollars in annual revenue within a decade.

In 2015, legal cannabis easily outpaced Girl Scout Cookies and e-cigarette sales.

End


Oregon Rec. Market Nets $60M in First Five Months of 2016

Oregon cannabis dispensaries have sold $60 million worth of recreational marijuana from the launch of 2016 through May 30, Eugene’s Register-Guard reports.

Lawmakers instituted the state’s temporary, early-access recreational cannabis marketplace last October. The state’s official recreational market is undergoing an extensive licensing process but should be fully functional by the end of 2016.

During its earliest months, Oregon’s recreational marketplace went untaxed; since January, however, recreational cannabis sales have been subject to a 25 percent excise tax. According to the Oregon Department of Revenue, the state had logged $14.9 million in recreational tax payments as of May 30, though about half of the state’s 319 dispensaries currently participating in the early recreational marketplace had as of last week failed to file their latest quarterly taxes.

“This is a new program, and some dispensaries are still learning about their tax obligations,” said John Galvin, who manages the Department of Revenue’s cannabis tax program. “We want them to be aware of what they need to do before they end up facing penalties for not filing or paying as they’re required,” Galvin said.

After the state’s official recreational marketplace comes online, the statewide excise tax will be lowered to 17 percent and localities will be allowed to vote for an additional 3 percent tax to help municipalities handle the regulatory costs of legal cannabis.

Oregon cannabis sales almost certainly spiked this month when on June 2 concentrates and edible products became available on the temporary recreational market.

End


Mexico’s Cannabis Reform Bill Stalled by Senate

Mexico’s senate has postponed discussing a bill to reform marijuana laws in the country until at least September, VICE reports, raising doubts that President Enrique Peña Nieto’s support for the proposal was anything more than good public relations.

“It looks like he never really wanted it,” Lisa Sánchez, drug policy expert and activist, said in the report. “It’s either that, or [the Institutional Revolutionary Party] now considers that Peña is the liability and his opinion is worth nothing from now until the next presidential elections in 2018.”

Peña submitted the legislation – which would have legalized medical marijuana and raised the decriminalized possession threshold – to lawmakers last April. During a speech to the UN General Assembly, he lauded the bill as a “historic step” in reforming the nation’s drug policies. However, Sánchez noted, it was the president’s own party (PRI) that stalled the bill.

In addition to providing medical cannabis and raising possession amounts, the measure would have reclassified possession as a violation of health legislation instead of a federal penal code violation – which, if enacted, would have freed about 13,000 people jailed in Mexico for minor marijuana crimes.

That reclassification was removed by the PRI, along with the possession thresholds, leaving just the medical portion of the bill – which was also changed by the party to favor the pharmaceutical industry.

“The congress will have to discuss it again but I wouldn’t trust our legislators,” Sánchez said.

End


Supreme Court Rejects Appeal to Save Montana MMJ

The U.S. Supreme Court has rejected an appeal against a Montana law that limits medical cannabis caregivers from providing to more than three patients, the Associate Press reports.

The rejection means that a controversial ruling made by the Montana Supreme Court in February still stands, and the state’s medical cannabis industry will be effectively snuffed out as of August 31, 2016. The February ruling upholds the state’s three-patient restriction law, a provision that was originally passed in 2011 following a series of federal raids against several of Montana’s large-scale cannabis providers and cultivation facilities.

Activists launched a petition campaign in March to delay the restrictions’ implementation until the end of the 2017 legislative session. The Montana Supreme Court, however, ruled in April that the restrictions would take effect on August 31. This, according to the court, would give cannabis patients and the Montana Health Department more time to handle any fallout associated with such a massive scaling back of the industry.

In turn, activists scrambled to assemble a voter initiative for this November’s voting season. The initiative, I-82, aims to undo the three-patient restriction and adds post-traumatic stress disorder to the state’s list of qualifying conditions for medical cannabis. I-82 would also establish licensing fees to help pay for the program, and would result in specialized provider licenses and annual inspections for Montana’s dispensary facilities.

Montana first legalized medical cannabis in 2004.

End


Smuggle Portland Invites Oregonians to Own a Piece of the Cannabis Industry

Oregonians can now easily invest in the legal cannabis movement. Smuggle Portland is raising $250,000 to transform their online store into a flagship location in Portland that sells high-end, cannabis-related accessories designed for women and Baby Boomers.

Community public offerings (CPO) give local businesses an option to avoid national banks and endorse alternative financing mechanisms. This approach is different from donation-based crowdfunding, like Kickstarter and Indiegogo. CPO investors get their money back plus interest. They also boost Oregon’s makers community whose sophisticated and sustainable products are sold by Smuggle Portland.

Smuggle’s co-founder, Renee Spears, said, “Baby Boomers and women are fast growing segments in cannabis. They don’t want to visit a headshop with black lights and blacked-out windows. We’re offering them a welcoming and elegant experience, both at our retail location and online. We want to help them stay healthy and conscious with products that epitomize the Pacific Northwest, cannabis lifestyle.”

Based on sales recorded for the Seattle Metro area, Portland is likely to sell over $200 million in cannabis alone in 2016. The associated products market is valued at twice that amount. This estimates the local ancillary market to be worth $400 million this year. Smuggle co-founder, Stephen Cahill, said, “We’re eager to meet our investors, share our business model, and demonstrate how we’re making decisions in this rapidly changing culture. I see our investors as thought leaders who want to align their money with their values.”

  • Any Oregon resident can invest until May 2017 at http://www.invest-smuggleportland.com/
  • Oregon is one of 10 states to have this unique, intra-state offering.
  • Women are the fastest growing demographic in the cannabis industry, and are responsible for
  • 70% of purchase decisions in America.
  • Baby Boomers are expected to account for 25% of market growth in cannabis over the next five years (Upstart Business Journal).
smuggle2
Smuggle Portland’s founders, Renee Spears and Stephen Cahill.

Smuggle Portland is co-founded by Renee Spears, owner of Rose City Mortgage and winner of numerous business awards in Oregon. Her co-founder is Stephen Cahill, a former MBA professor in business innovation at Pinchot University. Their staff includes a talented assortment of retail experts, product designers, videographers, system developers, and cannabis connoisseurs. They come from Nike, Banana Republic, and Liz Claiborne.

End


Supreme Court Rules Forced DUI Blood Tests Unconstitutional

Civil liberty advocates celebrated a major victory on Thursday after the U.S. Supreme Court ruled it unconstitutional for law enforcement officers to perform forced blood tests without a warrant on individuals suspected of a DUI, The Free Thought Project reports.

In Washington, this decision should lead to the overturning of that state’s DUI laws regarding cannabis because, currently, the only official method of testing a driver for THC-impairment is via blood test.

After the 2012 passing of Washington’s I-502, which legalized recreational cannabis, the state also established new DUI laws: in post-legalization Washington, drivers are not allowed to have more than 5 nanograms of active THC per milliliter of blood. For regular cannabis consumers, that is an absurdly low limit that essentially negates a regular consumer’s ability to legally drive themselves anywhere.

However, with forced blood tests now declared unconstitutional on a national level, Washington officials must seek a new way of checking drivers for THC impairment.

The Supreme Court decision ultimately ruled that breathalyzers do not require warrants but blood tests do because they are significantly more invasive: they both pierce the skin and leave behind a biological sample in the government’s possession.

End


Are Your Cannabis Customers Getting the Message?

Call it copy, text, messaging, content or whatever you like, but many cannabis business owners simply do not give the messages they send to customers the effort that is required in an age of customer control. Messaging on packaging, signs, ads, websites, product descriptions, and sales copy almost universally falls short — messages are limited, confusing, and in some cases just outright horrific.

Nobody ignores this part of their business on purpose. Customers just don’t behave like they used to. Smartphones and mobile devices have rendered tried and true sales and marketing methods that have worked for decades irrelevant. This dramatic shift has left business owners scratching their heads.

While the customer’s ultimate experience with your business (or product) is the foundation of growing your business, the messaging and copy that surrounds it can make a game-changing difference in how fast and how broad of an appeal your product has.

The idea that ‘one’ message will move everyone in your prospective customer base to buy what you sell is a very bad idea.

The motivations and needs that drive the purchase of any one product can vary wildly.

How We Make Decisions

Typically, we all make buying decision along two axes.

  1. Quick vs. Deliberate –or
  2. Emotional vs. Logical

Each quadrant represents a major buying mode that you can start taking into account when crafting messages of any kind.

4 Major Buying Mods

Look at the buying modes applied lightly to buying a strain cannabis flower.

  1. The Competitive buyer wants superior weed. Depending on their need, high THC or CBD percentages, or even flavor is their priority. Exclusivity is a plus too.
  2. The Humanistic buyer is about people and relationships.  They would like to know about the grower, would like to know about the seller, and especially wants to know if people like her have bought this strain. Is there a story behind the strain?
  3. The Methodical buyer wants value. More for less, sales, and added value excite the methodical buyer. Needs detailed data about each strain.
  4. The Spontaneous buyer wants to have fun. Novelty, a fun budtender, and description of the experience will get them excited.

Now look at how the four primary buying ‘modes’ come into play when buying a glass water pipe.

  1. The Competitive buyer wants a superior piece, one he can show off and is better than all or most of their friends. Will be interested in big brand names or exclusive artists/designs.
  2. The Humanistic buyer wants to know the glass blower or about the manufacturer and what they stand for.
  3. The Methodical buyer wants value. They will buy the most glass for the least amount of money.
  4. The Spontaneous buyer wants convenience. Make it easy and fun and this buyer will be hooked. Novelty design, unique features or anything that adds fun or dimension to the smoking experience.

What This Means for You

You’ll discover a whole new world of sales and growth opportunity when you understand of how to communicate to prospects in their buying modes. Not just for messaging that sells better but for crafting compelling customer experiences, even products.

Keep in mind this isn’t a comprehensive description of each buying mode’s needs and motivations, it is just a start. And we have yet to take into account how each behaves at each buying stage or detail their different processes for making a buying decision.

Wouldn’t all this be helpful to know when writing copy for a new product, designing packaging, writing strain descriptions, etc.?

You might recognize your own primary buying style or some of your customers here.  But the point is simple. If you don’t start communicating with your customers in a way they prefer to be communicated with and/or sell to them in a manner they prefer, your messaging will miss the mark. Period.

Your prospective customers have too many choices and too little time to stick around waiting for you to get it right, especially if your competitors are speaking their buying language already. It’s no longer enough to just communicate. You must speak directly to your customers felt needs. And from customer to customer—individual felt needs can be as different as oil and water.

Are you accounting for those differences in your messaging?

Now would be a good time to start.

End


Review: HISIERRA™ Bags

HISIERRA™ bags are one of many recent inventions made possible by the wave of cannabis legalization that’s swept the U.S. in recent years. Designed specifically for use in legal cannabis, HISIERRA™ bags are a sustainable, reusable, renewable and responsible child-resistant packaging solution that will prove useful for anyone in the business of dispensing medical cannabis — from the eco-conscious backyard caregiver to the dispensary owner whose main concern is staying state-compliant.

The bags themselves come in two size categories. The smaller size, called the ‘Daytripper,’ is 9″ x 6″ in dimension; this bag could easily hold up to a quarter of an ounce of flower — or much, much more if you’re willing to squash some nugs. The larger size, a.k.a. the ‘Weekender,’ is 12″ x 9″ and has a 4″ wide gusset base; for the dedicated cannabis consumer, this bag could carry several ounces.

In your hand, the bags feel sleek and sturdy. Aesthetic-wise, the bags are fairly minimalistic, though custom printing options are available on request, according to the company website.

The bags’ locking mechanism is very functional: the zipper slides back and forth easily at the top of the bag, but to access the contents inside you must push the zipper’s tab down into the bag’s seal. Under the Consumer Product Safety Commission Protocol and Standards, HISIERRA™ bags are certified “Child Resistant” under protocol 16 CFR 1700.20 and the Child Safety Standard ASTM D3475 and fully comply with the Poison Prevention Act of 1970. Each pouch is also food-safe verified.

To determine how well the bags can contain strong odors (an important factor for patients who must carry their cannabis with them throughout daily life), our testing team filled an HISIERRA™ bag with the skunkiest product we could find and placed it inside of a personal backpack. We couldn’t detect any odor leakage in the backpack after more than an hour of storage.

“It’s a dream come true for me, to be able to bring something that’s both earth-friendly and responsible packaging,” said HISIERRA™ founder and owner Mike Greenfield, a career packaging entrepreneur based out of southern California. “I’m able to combine two of my passions: that of the cannabis market and helping out as I can; and packaging — I’ve been in packaging my whole career.”

Each HISIERRA bag is constructed using bio-based resins largely extracted from non-GMO sugar cane. “The science behind it is it’s all about carbon,” Greenfield explains. “Instead of using fossil fuels such as crude oil or natural gas, we’re using plant-based biomaterials, and harvesting the carbon from them, changing it into a plastic material.”

HISIERRA™ goes beyond bio-based resins and eco-friendly material sourcing, however, because the entire HISIERRA™ production line is powered using 100% renewable, wind-sourced electricity. The factory is LEED certified Silver. “The air coming out of our factory is cleaner than the air coming in,” Greenfield jokes, but his emphasis on sustainable, renewable and Earth-friendly business practices is very real.

After brainstorming the new packaging technology concept just over two years ago, Greenfield sought help from family members to bring the idea to market — the company logo itself, three mountain peaks, is symbolic for Greenfield, his brother, and his father. “It’s a great opportunity for me to give back. It’s an opportunity for me to give back to my dad and my brother,” said Greenfield. “We’re a small family business, we’re not like one of the big monster companies out there. We’re building it out of the idea of providing a service to our customers.”

HISIERRA™ bags are available in dispensary boxes, which contain 60 bags each, or in a master case, which contains 7 dispensary boxes (or the magic number of 420 individual bags). The company is currently working to create smaller bag options to better serve the concentrates and edibles side of the industry.

You can learn more about HISIERRA™ bags at www.hisierrabags.com or reach out to Mike Greenfield directly at mike@hisierrabags.com.

We love seeing cannabis entrepreneurs put their ingenuity to work to come up with products that set a good example for the industry as a whole, and we’re excited to see what HISIERRA™ does next!

End


Portlanders to Vote on 3% Cannabis Tax Increase

Following unanimous decision by the Portland City Council yesterday, city voters will decide this November whether or not to embrace a 3% tax hike on recreational cannabis products, KOIN 6 News reports.

There is a 25% statewide sales tax currently in effect, but that will drop to 17% beginning January 1. After that point, local municipalities across Oregon will have the option of adding a 3% local tax for up to a 20% total tax rate. This November’s ballot measure, if successful, would earmark the money for the city and keep it from entering the general fund.

The move was proposed by Commissioner Amanda Fritz, who said it could raise up to $3 million each year. According to Fritz, the extra tax money would go towards drug and alcohol treatment, public safety, and supporting small Portland businesses.

“There’ll be a robust conversation at council about, are these the right items to dedicate it to? There’s been some suggestions to not dedicate it at all or to put it to something that’s not related to marijuana use, and I think the taxes work best when there’s a clear nexus between the people who pay and the people who benefit and to make sure that that’s fair,” said Fritz.

Oregon does not tax the sales of medical cannabis.

End


New York Gov. Doesn’t Know His State’s MMJ Law is Broken

Since its launch in January, the New York medical marijuana program has faced heavy criticism from patient and industry advocates for being too limited. However, in a surprising display of ignorance, New York Gov. Andrew Cuomo told reporters on Wednesday that he was unaware of any concerns over the state’s restricted and controversial medical cannabis program, The Journal News reports.

“I haven’t heard issues that people can’t find access,” Cuomo told reporters in Buffalo. “You don’t have one on every corner because you don’t have that kind of demand. But if you need the drug, you can get the drug.”

A recent survey of New York’s medical marijuana patients and caregivers by the Drug Policy Alliance unearthed serious flaws in the program. In their scathing report, the DPA found the program was plagued by unaffordable medicine and “overall inaccessibility.” Among the top concerns are an ongoing dearth of doctors who are qualified to recommend cannabis to patients, and a lack of information for patients who are seeking marijuana-friendly doctors.

“This should be something that [Gov. Cuomo] is aware of,” said Sen. Diane Savino (D), who has sponsored many of the state’s past marijuana measures. “Now that I know he isn’t aware of it, I’m going to make sure he knows.”

Meanwhile, New York Assemblyman Richard Gottfried (D) and other advocates worked up to the deadline in an effort to reform the program on behalf of struggling patients, but the session ended last week without any legislative action taken towards fixing the program.

End


Congress Neglects MMJ Reforms for Veterans

Congressional leaders have blocked medical marijuana reform efforts from both the House and Senate that would have opened the door for Veterans Affairs doctors to recommend medical cannabis to veterans in states where it has been legalized, Marijuana.com‘s Tom Angell reports.

In strong bipartisan votes last month, the legislatures each approved measures to the 2017 Military Construction and Veterans Affairs bill that would have blocked the VA from using funds to enforce policies preventing its doctors from recommending medical marijuana to their patients.

It had appeared that, with bipartisan approval from both chambers of the Congress, the protections would be secure for the bill’s final version. However, new bills are not complete until the differences between the House and Senate are reconciled into a final version of the bill by a conference committee made up of lawmakers from each chamber. Ultimately, neither set of marijuana protections were included in the conference committee’s final version of the bill.

The spending package was assembled late last night, and at 3:10 a.m. the House of Representatives voted 239-171 for its approval. The bill now returns to the Senate for a final vote before continuing on to President Obama.

It has been shown that medical cannabis could be an effective treatment for individuals suffering from PTSD, a potentially debilitating condition that is commonly faced by combat veterans.

End


Dr. Ethan Russo: Endocannabinoid Nutrition

In this week’s podcast episode, Dr. Ethan Russo — one of our earliest and most esteemed guests — returns to the show to discuss his latest article, “Beyond Cannabis: Plants and the Endocannabinoid System.”

Dr. Russo is a neurologist and psychopharmacology researcher, and is the former Senior Medical Advisor for GW Pharmaceuticals. He worked as a clinical neurologist in Missoula, Montana for 20 years, where much of his practice focused on the treatment of chronic pain. Today, Dr. Russo is one of the world’s leading researchers in the field of cannabis terpenes and the endocannabinoid system. He has authored several books about cannabis, cannabinoids, pharmacology, and rare botanicals, and he has published over 30 articles covering neurology, pain management, cannabis, and ethno-botany.

Listen along, or read the transcript below, as Dr. Russo and Ganjapreneur podcast host Shango Los discuss how various foods — including black pepper, kava, the common carrot, and more — can actually help balance the cannabinoid levels in your body.

Subscribe to the Ganjapreneur podcast on iTunes, Stitcher, SoundCloud or Google Play.


Listen to the podcast:


Read the transcript:

Shango Los:  Hi there, and welcome to the Ganjapreneur.com Podcast. I am your host, Shango Los. The Ganjapreneur.com Podcast gives us an opportunity to speak directly to entrepreneurs, cannabis growers, product developers and cannabis medicine researchers all focused on making the most of cannabis normalization. As your host, I do my best to bring you original cannabis industry ideas that will ignite your own entrepreneurial spark, and give you actionable information to improve your own business strategy and improve your health and the health of cannabis patients everywhere.

Today, my guest is Dr. Ethan Russo. Ethan Russo is a neurologist, psychopharmacology researcher and former Senior Medical Advisor to GW Pharmaceuticals. He served as study physician to GW for three phase three clinical of Sativex. He graduated from the University of Pennsylvania and the University of Massachusetts Medical School before residencies in pediatrics in Phoenix, Arizona and in child and adult neurology at the University of Washington in Seattle. He was a clinical neurologist in Missoula, Montana for 20 years and a practice with a strong chronic pain component. In 1995 he pursued a three month sabbatical doing ethno-botanical research with indigenous peoples in Peru. He is currently past President of the International Cannabinoid Research Society and is former Chairman of the International Association of Cannabinoid Medicines.

He has authored several books on cannabis, cannabinoids, pharmacology, and rare botanicals and has also published over 30 articles in neurology, pain management, cannabis, and ethno-botany. You can see his full lists of books and credits at the Phytecs website where he is presently Medical Director. To those of you who study his work and seek out his mentorship, he is the godfather of cannabis terpene research as well as a leader in research and popularization of the endocannabinoid system. Welcome back to the show, Ethan.

Dr. Ethan Russo: Well, thank you, it’s great to be back.

Shango Los: For those of you who are unfamiliar with the endocannabinoid system, you may want to hit pause and go back and listen to podcast episode number three where we speak with Dr. Russo about the endocannabinoid deficiency and he talks a lot about the ECS itself. Also, you might want to check out our recent episode with Dr. Greg Gerdeman on the popularization of the endocannabinoid system in human culture.

Today, we’re here to talk about Dr. Russo’s new article recently published in Trends in Pharmaceutical Science entitled “Beyond Cannabis: Plants and the Endocannabinoid System.” Ethan, with all of that, let’s start with a really solid basis for our discussion. For the folks who are not familiar with endocannabinoid system, yet, will you just give us a brief summary to kind of get them on the same page.

Dr. Ethan Russo: Sure, I’d be happy to. The endocannabinoid system, as one can tell from the name, was named after cannabis. This has to do with the fact that the main psychoactive component of cannabis, tetrahydrocannabinol or THC affects the system. One might first wonder, how long it would have taken to discover this system if cannabis were not around. In any event, for a long time after THC was first characterized in 1964, it was thought that it worked by altering some membranes in the brain, something like the way that alcohol works, but, in fact, it turned out that THC works on a receptor called CB1 — that’s for cannabinoid-1. That’s the main psychoactive receptor in the brain.

Some of the effects that THC has in making a person feel high, in reducing pain, affecting nausea and things like that, some of these things are mediated through this CB1 receptor, but, there’s also a CB2 receptor, cannabinoid-2. This one can occur in the brain under conditions of injury or inflammation, but, it’s mainly out in the body where it’s known as an immunomodulatory receptor. It has to do with immune responses, inflammation, and pain. But, those receptors are only one component of what’s called the endocannabinoid system. A few years later, somewhere in the early 90s, it was discovered that there were endogenous cannabinoids. Endogenous means within. It turns out that there are substances in our body that are THC-like, that work on these receptors, CB1 and CB2. The first one that was discovered was called anandamide. That’s taken from the Sanskrit word for bliss and the second is called 2-EG, 2-Arachidonoylglycerol, and both of these will stimulate the cannabinoid receptors.

Then, we have the receptors, we have the endogenous ligands, the chemicals in our bodies that work on the receptors and then the third component of the endocannabinoid system are the enzymes that make these endocannabinoids and break them down. We have this triad then, called the endocannabinoid system.

What does it do? I’ve already mentioned that this is very prominent in the brain. The main activity there is in regulating neurotransmission. I think most of the audience has probably heard of neurotransmitters. These would be things like acetylcholine and norepinephrine. They are the chemical signals in the brain from one nerve cell to another.

What CB1 does in the brain is inhibit the release of neurotransmitters. Let’s say, for example, someone has chronic pain, too much pain. That often goes along with an excess of a neurotransmitter called glutamate, which is stimulatory. If we have THC or anandamide that stimulates CB1 receptor will reduce release of glutamate and often act to reduce the pain. This is just one example.

However, although things started there, in terms of research, it turns out that the endocannabinoid system is a major homeostatic regulator of almost every physiological function in the body. I realize that’s a mouthful. Let’s break it down. Homeostasis is balance of function. What the endocannabinoid system will do in any given area of the body whether it be the brain, hormonal balance, appetite, digestion, is try and bring things back into balance.

In other words, if there’s too much of a neurotransmitter, stimulation of the endocannabinoid system will bring that down back into the range where it should be. In contrast, if there’s too little activity in the system, stimulation of the endocannabinoid system will bring it up back into balance. Almost any function of the body you can name is effected by the endocannabinoid system and it really points out the reason that cannabis is such a versatile medicine for so many conditions that are otherwise very hard to treat with conventional medicines.

Shango Los: I was thinking about that. The way that it regulates the system, it reminds me a lot of this vocabulary word that my acupuncturist used all the time from Chinese medicine that it tonifies the system. If you’ve got an excess, it brings it down to optimum, and if you’ve got too little, it brings it up to optimum, so that essentially, we’re creating, we’re feeding a regulator for our bodies, so if the ECS is healthy, all of these other systems will be healthy as well.

Dr. Ethan Russo: I think that’s quite appropriate and there are many parallels between some of the concepts in traditional Chinese medicine and some of what the endocannabinoid system does, right.

Shango Los: Up until now, your paper talks about how to feed and care the endocannabinoid system with food sources that are non-cannabis. This is a pretty big deal to everybody because up until now, we have been supplementing our endocannabinoid system, which is cannabinoids that are made in the body endogenously, with cannabinoids that we have been getting from cannabis, things like cannabidiol and actually most of the parts of the plant fall into that category, and now the idea that we can go to food sources for it is something that’s got people really excited, because not only is cannabis not easily available everywhere, but also, it certainly has a price point that’s higher than most foods. Your new paper suggests that these can be gotten from food sources. Why don’t we pick one category of cannabinoid and talk about the food sources that it is present in.

Dr. Ethan Russo: OK, we can start off with CB1. I’m sure that many of the listeners are interested in what plants outside of cannabis might have similar effects. Actually, it’s a short list there. If we look at CB1, which is generally of most interest to most people, way back about 2000, I was interested in the possibility of looking at some other plants that affected the CB1 receptor like THC does. We looked at salviadivinorum. It’s sort of a long story, but, we were interested in salvinorin A, which was clearly the most active molecule in that plant. We didn’t get any binding to the CB1 receptor, but interestingly, there was something else in the extract of the plant that seemed to work at that receptor. Along about that time, it was discovered that salvinorin A works on another receptor called the kappa-opioid receptor, and that its activity seemed to derive from that. Subsequently though, some other people looked at salvia again, and there is a relationship there that still is being worked out.

Another one that might be quite odd to people is the common carrot, daucus carota. It actually has a substance in it called falcarinol. This actually seems to have an antagonistic effect on the CB1 receptor.

That’s odd. What would it do? While most CB1 antagonists would reduce hunger and produce some other effects of that sort, but the main importance of this molecule is that if one were handling carrots at the same time that there was histamine around, it’s possible they’d get an allergic reaction. As a doctor, I don’t remember a lot of people getting a rash from carrots, but this is a possibility.

More interesting, I think, is another plant that may stimulate the CB1 receptor. This is piper methysticum, better known as kava. Kava is an interesting substance. This is made from a root of a plant that grows in the South Seas, so it’s common in Polynesia. This is pounded and mixed with water, and it makes a gluey sort of drink that is used as a method of relaxation. Typically, it doesn’t have alcohol, and we had an idea in the past of how this worked on a different set of receptors called gaba. It turns out that a few years back, it was noted that one component of it called yangonin seems to work on the CB1 receptor, and, traditionally, in a traditional dose of kava there may be enough to really affect things. Occasionally, people will say that they feel high in relation to kava, not just relaxed, but, again, this is a relatively recent discovery and needs to be examined more thoroughly.

I’ll mention one other in this category, and this is an unusual one also, this is in liverworts. This is a kind of primitive plant. There are two that have been described, the one from Japan and one from New Zealand. The one from New Zealand is called granular marginata. These particular liverworts have two substances in them that look like cannabinoids. One is called perrottetinene and the other, perrottetinenic acid. This was originally described about 20 years ago, and the author said, “they called them cannabinoids, but, interestingly, at that time, they didn’t test them for activity.” Recently, one of my colleagues, Juerg Gertsch in Switzerland has confirmed that these do act on the CB1 receptor.

Unfortunately, his paper is not yet published, so we can’t get more details. I will say this though, in relation to these plants, there are some … reports that people will find on the internet and they’re odd because some people say that they really got high from smoking this material, and others will say that it didn’t do anything. I’m not sure I can recommend that people experiment with this. It’s not necessarily healthy to try and smoke liverwort. Hopefully we’ll have more details on that. That’s one category.

Shango Los: Let’s unpack two of those. The salvia is around but hard to get for some folks, but, carrot and kava are both really common. Carrot you can just buy at any grocery store, and the kava kava you can get at most herbalists. I’ve got a tincture of kava right here on my desk. When I take it, it does have a relaxing effect to my human. I feel a certain amount of muscle relaxant and a little less care in the world, but, I don’t get that from eating carrots. How can we think about the right manner to ingest, and how does a normal person know the volume, or, is it just simply, “hey, eat more carrots and make yourself some kava kava tea occasionally, and you’re going in the right direction.” How can this help a common person to help their ECS using these?

Dr. Ethan Russo: Right, well, let’s go to the carrot first of all. I would remind listeners that this is actually antagonistic of the CB1 receptor, so, no one is going to get high from carrots. Similarly, it’s really unclear whether this falcarinol is active orally. We don’t know if it gets into the brain. I’ve never heard of anyone eating a carrot and having it reduce their hunger. Additionally, carrots are pretty high on the glycemic index. They have a lot of sugar in them the way they’ve been bred in modern times. I’m not sure it’s a diet food either. Certainly, the person that’s looking for legal highs shouldn’t go in that direction.

With a kava, what is a normal dose? With a tincture, I think people would just go with the directions on the bottle. If they’re making it themselves from the root, it probably shouldn’t be too much. The stuff is pretty nasty to drink, which is one reason that it’s better in capsules or as a tincture, but again, I have it on good authority from Alessia Ligresti, the author of the original article, that she does think that most strains of the kava do have a significant amount of yangonin in them. If someone suffers from anxiety or just needed it periodically, like, to take a test or go to court, I think that kava is usually a good, safe anti-anxiety agent. There were concerns about it in the past in relation to possible liver damage, but that was related to one particular preparation that’s not commercially available now. This has a long history of safe use in Polynesia.

Shango Los: I think the most important part I got out of that is just because we’re talking about food sources doesn’t necessarily mean you just eat this stuff and your ECS is going to be in better shape. It’s more about these are suggestions of places that you could continue your personal research to find out which of these might be better for you and determine the right amount for you to take. What we’re not saying is “this is just plug and play.” What we are saying is that these are some doors that are being opened by your research that shows that there are components in these plants that we need to figure out how best to introduce to our body. Does that sound like a good summary?

Dr. Ethan Russo: Yeah, that’s a great point. Again it’s, to me, maybe not the best place to start with CB1, but, it usually is the most interesting to people, being the psychoactive receptor. In fact, we may do better in this regard looking at some of the other plants for their effects, so, maybe we can transition into those.

Shango Los: Why don’t we go ahead and take our first break, because I’m excited to talk about CBG from food, and I think that’s going to take us a little bit. Let’s take a short commercial break and be right back. You are listening to the Ganjapreneur Podcast.

Marketing and brand agencies can be really unhelpful sometimes. You pay them and have meetings, but there doesn’t always seem to be real value created. Sure, they may make you a logo or a website, and you talk about the image your company wants to project, but that is not always reflected in the bottom line in the form of actual revenue. For a lot of start-ups, everything has got to feed the bottom line, just so they can survive.

That’s what Blunt Branding does. They feed your bottom line. Blunt is very different from other agencies because their principals, Kiersten Nelson and Anthony Garcia are experts in psychological marketing. For example, they don’t just write copy for your website, they write copy that includes hooks and triggers for every Myers-Briggs personality type. Most copywriters tend to write only for people who think like them. Blunt Branding does better than that. They reach all your potential customers. In fact, if there’s a certain kind of customer that you don’t want, say, argumentative folks, Blunt will write you copy that attracts everyone else, but will tend to repel the kind of customer that gives you grief. I’m not kidding. This strategy is used by their attorney clients all the time. Your brand is much more than a logo, you see, most customers wait for some company to wow them with something more than they came shopping for, especially when there are so many options, right. They’re looking for a brand to anticipate their questions or solve their problems or just make them feel seen, heard and valued.

I know that can sound corny, but we all know that we buy from the companies we feel most engaged with, and Blunt Branding will get them climbing over your competitors to get to you. If you cannot risk business failure, you should be working with a marketing team who understands that their goal is not just to make you pretty, but to directly increase your sales success, too. Go to BluntBranding.com to find out more.

Welcome back. You are listening to the Ganjapreneur.com Podcast. I’m your host Shango Los. Our guest this week is neurologist and cannabis researcher, Dr. Ethan Russo.

Before the break, we were talking about different food sources that could work with the CB1 receptor to help manage your endocannabinoid system. We’re ready to move on from there to talk about CBG, cannabigerol, and, Ethan, I understand that you have found food sources for that, or, maybe just one. Your paper talks about a flowering plant in southern Africa. Is that something that we can even get in the United States?

Dr. Ethan Russo: Oh boy, that’s tough. This is an odd one. Again, traditionally, it’s been thought that cannabis was the only source of cannabinoids, but, it’s turning out not to be true and that was the reason for writing this article. Actually, more than 30 years ago, there was an obscure article written in German about finding cannabigerol, one of the so called minor cannabinoids of cannabis, in this flower from southern Africa. It’s called helichrysum umbraculigerum, and, although it is, I understand, a common roadside plant in South Africa, they’ve got very strict laws about intellectual property in South Africa, and it’s not something that you’ll find commercially. I’m happy to say that we have legally obtained a supply of this and aim to investigate it further.

What the original article said was that two cannabinoids, cannabigerol, which is the decarboxylated form, it’s lost its CO2 and its precursor, the cannabigerolic acid, the acid cannabinoid were found in this flowering plant. Unfortunately, the original article never stated the concentration. The issue is, is there a significant amount of these chemicals in this plant, and could it possibly be a non-cannabis source for cannabigerol? That’s the question. Unfortunately, we don’t have the answer yet. We’ve just procured the plant and we’ll be doing the bio-chemical assays to try and answer that question.

It raises a bunch of other issues. In most countries, this is not a big deal. Cannabigerol is not a scheduled compound, meaning it’s not forbidden, but, in the U.S. it would be considered illegal. Now, all of a sudden, you may have a situation of this attractive flower could be illegal to grow in the U.S. We just don’t know what will happen with that. It’s just another example of quirks in the law. Unfortunately, in my opinion, these laws are not subject to the teachings of science. In this instance, it’s guilt by association. Cannabigerol happens to be produced by the cannabis plant, and I’m not sure that legislators necessarily care whether it appears in another plant that happens to have a pretty flower and have other purposes.

Shango Los: It’s like getting blamed for something that your cousin did.

Dr. Ethan Russo: Yeah, you bet.

Shango Los: Since we’re not sure if we can even get our hands on it, let’s move right along to anti-inflammatories. You’ve got a nice list of foods where we can get some caryophyllene. What are those foods and whatt’s the best way to go about enjoying them?

Dr. Ethan Russo: First, there’s just a little background. Caryophyllene is what’s called a sesquiterpenoid. That means it’s a 15 carbon terpenoid. It’s got sort of a balsamic aroma. People may think they’re unfamiliar with this, but I bet they are, actually, because it is one of the components of black pepper and it’s responsible for some of its taste and its effects, but, caryophyllene appears in a bunch of different plants and it’s not just black pepper, but, many others.

Shango Los: A couple others that you mentioned in your paper are chili peppers, and ginger, and euphorbia, which I was surprised. It’s probably a different euphorbia than is growing in my yard.

Dr. Ethan Russo: We need to back up a little bit. Caryophyllene beyond cannabis and the black pepper is going to be in cloves, it’s going to be in hops, and melissa, lemon balm. The importance of this is, about 10 years ago, again, Juerg Gertsch in Switzerland discovered that caryophyllene is a CB2 agonist. To reiterate, CB2 is the non-psychoactive receptor. That’s important in treating inflammation and pain. Caryophyllene, which happens to be in cannabis also is at once a terpenoid and a cannabinoid in its own right, and it was well established long before we knew it had this effect on CB2 that caryophyllene is a very effective agent in treating inflammation and pain. The copaiba balsam, copaiba is a tree in South America and its sap, which has a lot of caryophyllene in it has been used traditionally by indigenous groups and other people in South America to treat wounds, arthritis, and things of this sort. Certainly, this is one instance, where if you had steak au poivre, you have a good intake of black pepper, you may be positively modulating your endocannabinoid system. If anybody was thinking that there aren’t accessible agents that could help tune things up with respect to the ECS, here is a good example.

Shango Los: Is black pepper, in this case, this is one of the cases where it is appropriate for us to simply eat it, where we don’t necessarily have to make a tea or a tincture or something like that to make it bio-available, we can simply just eat it and our body will process it, and it will support the ECS.

Dr. Ethan Russo: I believe that’s true. That doesn’t mean that everybody has to have a huge amount, but, I’m one of those people that tends to put black pepper on everything, and I did that long before I knew that it might be helping me.

Shango Los: Right on then … go ahead.

Dr. Ethan Russo: Black pepper is really interesting, because that’s not the only effect it has on the ECS. It also effects another related system that’s called the TrpV1, that’s the transient receptor potential vanilloid 1. This is also considered part of the endocannabinoid system. It’s going to be most familiar to people from the other kind of pepper, red pepper, capsaicin, the chili peppers. Capsaicin is a TrpV1 agonist, so it’s famous or infamous for its burning sensation. What’s interesting about the TrpV1 receptor is although some of the agents that stimulate it, like capsaicin, burn. That burn goes away after a while because the receptor becomes desensitized. This can be used to advantage in treating pain. People may have seen on TV, ads for ointments that have capsaicin in them and they’re used to treat pain, particularly nerve based pain. For example, if someone has diabetic neuropathy, a burning pain in the extremities, if they apply this kind of ointment with capsaicin in it, say, three times a day over a period of time, it can actually reduce the pain. It’s very cumbersome to do, but it can be effective.

Interestingly, there are other things that do this. Ginger has TrpV1 agonist in it, and again, black pepper. This is a situation, we’re not sure how much of this gets absorbed, and whether just eating foods that are rich in TrpV1 agonists will help with, say, arthritic pain, but, we do know, and this is odd, that people who have inflammation of the gut, say, with irritable bowel, sometimes will benefit from regular use of spicy food, particular regular use of chili peppers. People are well aware that in certain cuisines, say, India, southeast Asia, that chilies are in almost everything, and this may be one of the reasons.

Shango Los: I’m starting to get the idea that this research is pretty bleeding edge. We’re talking about a lot of these different examples, but how to get it into our body, and in what amounts, and what the exact effect seems to be open to discussion and additional research. It sounds like not only do we want to look more into these examples of food sources, but we also don’t entirely know how best to get them into our endocannabinoid system, so, we’re kind of at the beginning of this new family of research.

Dr. Ethan Russo: That’s absolutely true. I’m very excited about this. There is work that’s yet to be done. Like anything, particularly dietary, you would not want to make it your sole focus by any means, but, certainly these foods, your body is going to rebel if there’s too much, so that would be one signal. There actually are other areas where we can give some guidelines on how to use food to optimize the ECS. We haven’t heard what may be the best part yet.

Shango Los: Meaning that research hasn’t been done yet, or that we just haven’t gotten to that point in your paper yet?

Dr. Ethan Russo: The latter. I think we’ve got another chapter coming up here that might be more helpful on a practical level for people.

Shango Los: Right on; I follow what you’re saying. One of the things that struck me, in your paper, you’re talking about additional CB2 agents that are available to us, and there, right at the top is echinacea, and in one way it surprised me to see echinacea there because we take echinacea to get rid of or to postpone our colds all the time, but, I never really considered it something that was going to be acting upon the endocannabinoid system. I’ve got a two-part question. To what degree or what is the mechanism for echinacea to act upon our ECS, and, you know, we’ve been using this plant for thousands of years, and how do we understand that humans came across using these plants? Was it simply by trial and error?

Dr. Ethan Russo: That’s interesting. First of all, for people who aren’t familiar with it, echinacea, usually it’s the root that’s used, and this is a Native American plant. How Native Americans discovered this is hard to say. It could have been empirical, you know, that they were looking for food and someone tried this. It has an unusual effect, it has a sort of local anesthetic effect in the throat, and somebody may have tried to eat this in a moment of hunger, and discovered that it had this local anesthetic effect when they had a cold, and one thing leads to another. I wouldn’t rule out that some of this could have been learned by divination, although, less common in North America, certainly in South America, many useful medicinal plants are discovered by use of ayahuasca, the vine of the soul, and what plant do I need to take care of this ailment. In this instance, I think we may never know how people happened along this knowledge.

Shango Los: I have to follow up on that one. To be discovered via divination, using ayahuasca, I think that what you’re pointing at is when the person would intake the ayahuasca, this would open up their energy centers to be able to get information from the surrounding plants, and somehow the plants would let the person know that they should look towards this plant. Is that what you’re suggesting?

Dr. Ethan Russo: Yeah, it is, and I realize…

Shango Los: That’s great.

Dr. Ethan Russo: This may go far beyond the credence of many of our listeners, but I’ve seen it happen in South America, and I wouldn’t rule out that the same happened in North America among the indigenous peoples. We modern humans have largely lost this capability, but, either through happenstance or experimentation, it was discovered by people that echinacea root had useful properties in reducing not just the pain of a sore throat, but also in shortening the duration of this kind of illness. As it turns out, though, this is an agent that works on CB2, and so it may have a lot more applicability medicinally than just trying to shorten the duration of your cold. CB2 agents, again, seem to be very useful in reducing inflammation and also reduce fibrosis. Fibrosis is scar tissue.

Let’s give one example. We have an epidemic of hepatitis C that leads to scarring, fibrosis of the liver, and a CB2 agent taken regularly could help prevent that. This is a real possibility. Additionally, these CB2 agents may be useful in autoimmune diseases, but we don’t know yet whether that’s the case. Again, this is one of those areas that although it’s tantalizing, we’ve got at this point, many more questions than answers.

Shango Los: You’re right, it is tantalizing. Before we go to the commercial break, I want to follow up with one more question about the divination aspect of it. In the introduction, I mentioned that you did a sabbatical in Peru with the indigenous people studying their healing botany, and I’m sure that was really interesting. In looking at the list of books that you had written, I wish I had it in front of me, but I believe that you wrote a book about your experience in Peru. If I go and pick up that book, do you write about divination in that book? I’d love to hear your thoughts on that, which today is not the place, but, would those thoughts be in that book?

Dr. Ethan Russo: Yeah, the book I wrote called “The Last Sorcerer, Echoes of the Rain Forest,” is actually a work of fiction, and yes, it does discuss divination, but that was a fictional account.

Shango Los: Right on, very good. We’re going to take another short break and then we’re going to talk some more about this, about how to support your endocannabinoid system with common foods. We’ll be right back. You are listening to the Ganjapreneur.com podcast.

The Ganjapreneur Podcast is listened to by tens of thousands of cannabis entrepreneurs and enthusiasts every single week. These folks are most likely your target customers, and we’d like to introduce you to each other. Our down to earth and information rich commercial breaks can deliver your message to the cannabis business community and others who just find relief in getting high. If you want to reach out and connect with our audience in the most personal way that we can offer, go ahead and drop us an email at grow@ganjapreneur.com, and we can talk about you becoming a commercial sponsor of the podcast. Thanks for listening and being a part of the Ganjapreneur family. Now back to the show.

Welcome back. You are listening to the Ganjapreneur.com podcast. I am your host, Shango Los. Our guest this week is neurologist and cannabis researcher, Dr. Ethan Russo. Ethan, we were talking about some of the things that are more common that folks could eat that could help their endocannabinoid system, and one of the things that you mentioned in your paper that I actually have quite often is galangal root. In the same category is apples and blackberries, and they all contain the flavanoid, camphorol, which can be taken to boost serum AEA levels. I’ve got to admit, I don’t actually really know what AEA levels are and why that’s a benefit. Why don’t you break that out a little bit for us.

Dr. Ethan Russo: Sure, so, AEA is just short for anandamide. The full name of anandamide is arachidonyl ethanolamide. Again, it’s that first discovered endogenous cannabinoid that works on the CB1 and CB2 receptors. AEA levels in the body are regulated by an enzyme that breaks it down called FAAH, fatty acid amino hydrolase. There are actually substances available in nature that inhibit FAAH. FAAH inhibitors, if they’re around will boost anandamide by preventing its breakdown. It would sort of be analogous to what an SSRI anti-depressant does with serotonin, say, Prozac for example, but in this instance, working to boost anandamide levels. The substance you mentioned, camphorol is in galangal root, which is used in, say, Indonesian cooking, but, more commonly, particularly here in the northwest would be apples and blackberries, we’ve got tons of them. There are small amounts of camphorol in those, and it may be that, if you’ve got a good intake of that, your apple pie or blackberry pie, may inhibit the breakdown of anandamide and give you a boost that way, it’s really possible.

Shango Los: Anandamide is pretty popular. Are there any other foods that we should be aware of that’s got anandamide in it?

Dr. Ethan Russo: Yeah, the problem is, yes, there is. The most obvious example is a recent discovery that truffles, specifically the black truffle, tuber melanosporum actually contains anandamide. Anandamide normally isn’t present in plants, but then I have to remind the listeners that fungi are no longer considered plants. They’re actually more like animals than plants, and they’re in a group of their own at this point, but, the way that the truffles use the anandamide is a little bit different. They develop more anandamide as they get darker in color. It has to do with the production of melanin, the dark pigment that makes the truffles black or produce darker skin as in tanning or in darker races. This is interesting. The problem is that it’s not enough to eat anandamide. Unfortunately, for our purposes, even if you had access to a bunch of truffles, the anandamide in them would be broken down in your digestive track before you had a chance to get it absorbed out into the body. It may be a better strategy to use the galangal or the apples and blackberries to inhibit the breakdown of anandamide and increase its amount in the body that way.

Shango Los: That makes a lot of sense. Chances are, the black truffle taro chips that I have in my kitchen are probably not going to be the best source, either.

Dr. Ethan Russo: No, but, if you enjoy them, have at it.

Shango Los: One of the things that jumped out at me in the paper was your pointing out that chocolate does not have cannabinoids, as is commonly thought, but there actually are other benefits. What are those other benefits?

Dr. Ethan Russo: Right, so, just to reiterate, there are no endocannabinoids in chocolate, however, it may have the same benefit, it has other health benefits, particularly if it’s not sugar laden, but, it contains a couple of ingredients called ethyleneamines that are FAAH inhibitors. When someone eats chocolate regularly, they may be boosting their anandamide level that way, so it’s an indirect effect rather than a direct one.

Shango Los: That makes sense. Let’s finish up with prebiotics and probiotics. We hear a lot about probiotics in the media, as well as in growing our gardens, but in this application, it’s different. What are the prebiotics and probiotics that are coming from food sources that we should be aware of?

Dr. Ethan Russo: First, let’s define some terms. Probiotics, probably more familiar to people, but won’t be familiar to everyone. Probiotics are actually bacteria that are native to our gut. These are beneficial bacteria. If you didn’t have any, chances are you couldn’t survive, but, they actually have a key role in digestion and prevention of disease. These are going to be most familiar to people in the form of yogurt, so, lactobacilli, also bifido-bacteria. We have this unfortunate concept in our society that bacteria are a bad thing, we couldn’t survive without them, and like anything else, there are good bacteria and bad bacteria. In this particular instance, the good bacteria help prevent diseases caused by the bad bacteria. You hear a lot about e. Coli epidemics, one of the ways to stem that kind of affliction is by having a healthy gut with the right bacteria. The first thing to understand is we can supplement this by having yogurt in our diet, or, people that don’t use dairy products could get some of the same effects with kefir or other fermented foods, particularly things like sauerkraut, or lacto-fermented vegetables. They can be made without any dairy products, just through natural fermentation as lactobacilli are in nature, naturally. Sour dough would have these as well, and these are just absolutely key to health.

The other side of the coin is prebiotics. Prebiotics are vegetables that feed the probiotics, the good bacteria. Some of these are going to be quite familiar, and others not so much. The familiar ones would be the LEACI, these are members of the onion family: your common onion, garlic, leeks. This is another one of those situations, I put onions in almost everything, and it’s a very healthy food in terms of feeding the good gut bacteria, but, there are many others that also have this effect, particularly things that contain a chemical called inulin, or other fructooligosaccharides, that’s a mouthful, so let’s just call them FOS for short. These would include things like acacia senegal, gum arabic, and some less familiar foods, chicory root, Jerusalem artichokes or sunchokes, and things like dandelion greens and burdock root. Burdock is quite popular in the far east, probably much less familiar to folks in the west. Any of these foods, again, are just dynamite in terms of being feed-stock for the beneficial bacteria. Although you can’t always get dandelion grains at the market, a lot of these things are available in capsule form as supplements. The acacia fiber, which is particularly good for people with gut problems is available as a commercial product online and can do wonders for people with, say, irritable bowel syndrome.

Shango Los: One of the things I like about the prebiotics and probiotics section is we have finally hit on something that people can really apply themselves to get their hands on. It sounds like a lot of the prebiotics are plants that we can wild craft, and many of the probiotics, heck, I’ve got a crock going, making some sauerkraut right now that is dairy free, so, look, I’m making a probiotic that is helpful for my endocannabinoid system. I think it’s really helpful to be able to focus in on something that we can actually do that’s tangible to help ourselves. That kind of leads me to where I want to summarize here as we come to the end of the show. It sounds like … We’ve talked about a lot of different plants today, and we know varying amounts about them. It sounds like research is taking place and it’s very promising, and it sounds like it would be a great field for people interested in the endocannabinoid research to go into and that it’s also a good field for just the simple citizen scientist to get into the research and learn more, and tell your friends and certainly tell patients.

To cap us off for the day, in retrospect, looking at all of these different options, what would you just ell a friend over dinner would be three or four foods that they could find relatively easily that would help them out and be a great place to start. Just, like, add these to your diet, and you’re going to be better than without them?

Dr. Ethan Russo: Yeah, it’s great to have the opportunity for a change, give people practical advice in this regard, but I would certainly encourage people to incorporate sauerkraut in their diet, other lacto-fermented foods like naturally fermented pickles, kimchi is excellent in this regard, in the Korean section of the supermarket. Again, the LEACI, the onions, garlic, leeks, and particularly people with gut problems, the acacia senegal, gum arabic, fiber is excellent in helping to treat that kind of problem.

Shango Los: Fantastic, now everybody has a solid to-do list. Ethan, I know that the show has gone longer than I’ve asked for your time today, so I’m going to wrap up now. Thank you so much for being on the show, and introducing us to this new area of research that we can all get excited about and start learning more for ourselves.

Dr. Ethan Russo: Thank you for the opportunity.

Shango Los: Dr. Ethan Russo is an internationally beloved neurologist and cannabis researcher, currently Medical Director at PhytECS. To find out more about Dr. Russo, you can go to Phytecs.com, that’s P-H-Y-T-E-C-S, or simply search his name, Russo, R-U-S-S-O, on researchgate.net, and start reading his research. If you want a copy of the article we were talking about today, you can email him directly. It’s still out for sale right now, so we’re not able to post it on the website just yet, but if you want to email him at EthanRusso@comcast.net, he will send it to you personally. Also, remember that Dr. Russo is an active international traveler, so don’t expect an immediate response.

You can find more episodes of the Ganjapreneur.com podcast in the podcast section and also in the Apple iTunes Store. On the Ganjapreneur.com website, you will find the latest cannabis news, product reviews, and cannabis jobs updated daily, along with transcriptions of this podcast. You can also download the Ganjapreneur.com app in the iTunes and Google Play shops. For info on me and where I will be speaking, you can go to ShangoLos.com.

Do you have a company that wants to reach our national audience of cannabis enthusiasts? Email grow@ganjapreneur.com to find out how. Today’s show was produced by Michael Rowe. I am your host, Shango Los.

End


Snoop Dogg Facing Trademark Infringement Lawsuit by Canadian Sports Network

Maple Leaf Sports and Entertainment (MLSE), a professional sports network based out of Toronto, Canada, has filed a trademark infringement lawsuit against Leafs By Snoop, a cannabis company that offers a selection of marijuana products hand-picked by the internationally acclaimed rapper/ganjapreneur Snoop Dogg.

MLSE, the parent company for the Toronto Maple Leafs professional hockey team, filed its opposition suit on June 8 and requested time to explain why the Leafs By Snoop logo infringes on the network’s own design.

The logos, pictured above, bear similar design choices but sport obvious differences in color and font selections.

According to Christopher Sprigman, an intellectual properties professor at the New York University School of Law, “The Maple Leafs might say that their brand has been tarnished by confusion over Snoop’s new logo.”

“That’s quaint but a tough argument,” Sprigman told the Turner Sports Network. “I don’t see a lot of overlap between Colorado pot smokers and Maple Leafs fans.”

Neither MLSE spokesman Dave Haggith or Snoop’s attorney Lawrence Apolzon chose to provide statements for TSN’s report.

Snoop Dogg is one among many American celebrities to get involved in the newly-legalized industry. Leafs By Snoop launched last November, and the company currently offers a wide variety of cannabis flowers, edibles and concentrates in dozens of dispensaries throughout Colorado.

Other celebrities, including Willie Nelson and Whoopie Goldberg, have also created personal marijuana brands.

End


First Legal Cannabis Crops Harvested in Uruguay

International Cannabis Corp and SIMbiosys harvested the first legal marijuana crops in Uruguay earlier this week, reaping about 300 grams each, which will be sold at licensed pharmacies in the South American nation, according to a report from High Times.

The plants were planted in February in the companies’ facilities in Montevideo under the authority of the Institute for the Regulation and Control of Cannabis. It is estimated that the initial cultivation process, including drying, manicuring and packing, will conclude by August. Uruguayans will then be able to buy up to 40 grams per month at a set price of one euro or $1.20 per gram. In addition to the Montevideo-metropolitan-area pharmacies – which will be closely monitored – 3,000 people have been registered as individual growers and 15 cannabis clubs will be permitted to grow up to 99 plants each.

Under the law, manufacturers cannot brand their strains or products and all advertising is banned. Tourists are also barred from purchasing cannabis at the retail locations. The drug will be sold at the pharmacies in packets of five or 10 grams and the stock will be renewed every 15 days.

The Uruguay Medical Union is also developing a model for cannabis therapies.    

End


Massachusetts Legalization Campaign Submits Excess of Signatures

The Campaign to Regulate Marijuana Like Alcohol submitted more than 25,000 signatures to Massachusetts officials on Tuesday, far surpassing the 10,792 required to add a recreational marijuana proposal to November ballots, the Associated Press reports.

Under the plan, people 21-years-old or older would be allowed to possess up to 1 ounce of marijuana for personal use. Retail sales would carry a 3.75 percent excise tax, on top of the current 6.35 percent sales tax.

Jim Borghesani, spokesman for the organization, indicated that the signatures were submitted to officials well before the deadline, clearing one of the hurdles used by regulators to invalidate petitions. Having more than double the required signatures will also help to ensure they can cover any signatures are disqualified for various reasons, such as being ruled ‘stale’ – an issue advocates in Michigan are currently battling.

Republican Gov. Charlie Baker, Democratic Attorney General Maura Healy, and Democratic Boston Mayor Marty Walsh have been outspoken opponents of legalizing marijuana in the state, calling it a “gateway drug” while the state is grappling with an opioid crisis.

A lawsuit that claims voters who signed the petitions were not told the marijuana products may contain “potent” levels of THC has not yet been ruled on by the Supreme Judicial Court.     

End


DEA Announcement Expected Soon, Rumors Fly

If you follow cannabis news with any regularity, you likely noticed the controversial headline, “U.S. Gov’t Will Legalize Marijuana on August 1,” published June 18 by a weekly paper out of Santa Monica, California.

The Santa Monica Observer reported on Saturday that an anonymous attorney for the Drug Enforcement Agency (DEA), with inside knowledge of the situation, disclosed plans by the DEA for the rescheduling of cannabis to Schedule II on the Controlled Substances Act, effectively legalizing medical marijuana in all 50 states. The catch is that patients would require a doctor’s prescription and the product would have to be handled by pharmacies, not dispensaries or caregivers — and it could potentially spell utter catastrophe for the legalized industry.

Cannabis is a Schedule I substance in the eyes of the federal government, with “no currently accepted medical use.” Moving marijuana down one step would put it on the same level as oxycodone, morphine, methadone and other opiate prescription drugs. It is widely-accepted among cannabis advocates, however, that the most ideal course of action would be to remove cannabis entirely from the Controlled Substances Act.

The Observer‘s article has been both cited and criticized by other cannabis publications, including a scathing counter piece by The Daily Chronic that argues professional journalism ought to rely on more than just a single source, speaking anonymously.

In April, the DEA said it would announce its decision about whether or not to reschedule cannabis during “the first half of 2016.” Anticipating the announcement, The Denver Post recently published an editorial by Tom Downey — a regulatory attorney for the Colorado law firm Ireland Stapleton Pryor & Pascoe — in which he proposes a plan for the DEA to facilitate the responsible regulation and normalization of cannabis.

With the final days of June ticking away, the Observer‘s piece could be either an actual leak of privileged information or a ploy to generate discussion and readership, playing off the suspense of waiting for an historically dogmatic and myopic agency’s decision about one of the most hyped progressive movements in decades.  In either case, we are expecting a major announcement from the DEA in a matter of days.

Jedidiah Haney, Interim Board Secretary for The Cannabis Alliance, told Ganjapreneur that he had been initially skeptical of the reclassification rumors, but that he didn’t completely rule them out. “Anything is possible,” he said. “The government is playing shadow games.”

According to Haney, a Schedule II reclassification would require an entire re-writing of most legalized states’ marijuana laws, both medical and recreational. When asked whether Schedule II might embolden the federal government into taking action against state-legal marijuana businesses, Haney noted that the government’s current policy of non-enforcement is a result of the Cole Memo, established in 2013, which says the federal government will not take action against state-legal cannabis companies so long as such enterprises are compliant with local regulations.

However: “It’s a memo,” Haney said. “At the end of the day it’s an opinion. That opinion can be fickle and it can be charged to change. But is it worth federally prosecuting all the people that have engaged in the experiment? Probably not.”

Dr. Dominic Corva of the Cannabis and Social Policy Center told Ganjapreneur that he believes the DEA will bring cannabis down to Schedule II, “because that’s a move that’ll be supported by the pharmaceutical … and banking [industries].”

“I just don’t see the DEA being any more progressive than they have to be,” Dr. Corva said. A Schedule II reclassification would remove the federal penalties preventing corporate banks and pharmaceutical companies from entering the cannabis space, and Dr. Corva anticipates that the opportunity to enter the nascent, flourishing market will be seized.

Dr. Corva sees the post-rescheduling marijuana industry as one that will be forced to juggle persisting cultural stigmas about cannabis use against a growing need for a more normalized understanding of the plant itself.

“The work to be done to make cannabis not be perceived as a social threat is extremely incomplete,” he said. “The businesses don’t get that they have to convince the public that this is okay … and they aren’t putting any effort into that.”

For Dr. Corva, whether or not the federal government decides to take action against state-legal enterprises is a less concerning issue:

“The Cole Memo itself, however it will be revised — which I anticipate it will — could loosen things up, but here’s the problem: it’s not just about the feds, it’s about local politics. And it’s about cultural politics. And rescheduling is not going to change anything about either of those — the feds can reschedule, but the states might not. And whatever the states do, their local jurisdictions are going to have to opt in or opt out.”

In any event, we will be watching closely (and anticipate the same from everyone involved in the cannabis industry) for the DEA’s upcoming and undoubtedly game changing announcement.

End


New York Legislature Fails to Pass Any MMJ Related Bills At Session’s End

The New York legislature failed to enact any of the proposed fixes to the state’s medical marijuana program before the legislative session ended last week, despite two bills – one allowing nurse practitioners and physician assistants to certify patients and another making the physician list public — passing the Assembly.

Assemblyman Richard Gottfried (D), who sponsored the initial Compassionate Care Act, said the Republican-led state Senate failed to show any willingness to enact the Assembly-approved proposals that would have helped patients struggling to get enrolled in the program, and that the Health Department should “take the steps within its power” to improve the program without legislators having to introduce legislation.

“There are still too few practitioners participating in the program, and patients should not have to try to find information through social media or randomly calling doctors,” he said in an email with Ganjapreneur. “Without action, New York will continue to deny care to tens of thousands of seriously ill patients.”

Two other bills, one to remove the 10 milligram limits and add eligible conditions, and another adding chronic pain not associated with a listed condition, failed to make it to the Assembly floor for a vote.

Last week, the Drug Policy Alliance released a report that found New York’s program is plagued by unaffordable medicine and “overall inaccessibility.” Kate Bell, the legislative analyst in charge of New York for the MPP, said they are “disappointed” at the legislative failures, calling the program “deeply flawed.”

“New York has one of the smallest number of patients per capita because it is so difficult for patients to access their medicine. Expanding the list of providers who can recommend medical marijuana is something that has been effective at expanding access in other states, and chronic pain, which is not included in New York, is one of the most common conditions for which patients use medical marijuana elsewhere,” she said in an email. “Adding chronic pain to the list of qualifying conditions could also have helped reduce New Yorkers’ use of far more dangerous opioid painkillers.”

Julie Netherland, director for the DPA’s Office of Academic Engagement, says that even if these measures had been enacted by the legislature, the program would still be unaffordable for most present and future enrollees.

“More and more patients are basically saying they are going to continue purchasing medicine on the black market because it’s so much cheaper,” she said. “So we had hoped that, with the proposed legislation, [New York] could expand the market and bring the costs down — so that is still a major concern.”

Netherland explained that the low-enrollment, high-cost nature of the program is “challenging” for the five companies approved to cultivate and dispense cannabis in the state, but none have indicated to her that they plan on dropping out of the program.

However, it remains difficult for those producers to open up dispensary sites quickly because they, so far, have probably not seen returns on their initial investments and fees paid to the state.

“[Owners] have to jump through a lot of hoops,” Netherland said. “I think that creates a lot of costs for them.”

Under the law, the Health Department Commissioner has the power to make any of the changes that have been proposed by lawmakers, but have thus far decline to do so, forcing the issues to be hashed out in the legislature.

While the Health Department does not comment on pending legislation, in an email they lauded the 5,066 certified patients, and the more than 600 participating physicians enrolled in the program’s first five months.

“As these numbers continue to grow, our focus … will remain on ensuring that patients whose doctors believe they can benefit from medical marijuana have access to treatment,” the statement read. “We will continue to monitor the program and consider options to make it as effective as possible.”

End


New Health Office in Las Vegas Will Cut Down Wait Times for Medical Cannabis Approval

Officials in Nevada have opened a Division of Public and Behavioral Health office in Las Vegas in an effort to cut down on wait times for patients enrolled in the state’s medical marijuana program, according to an Associated Press report.

The new office is the result of a partnership between the state and Nevada Dispensary Association.

Patients will now be able to bring their applications directly to the office and could see their prescriptions filled the same day, removing weeks of waiting by patients who previously had to mail their doctor recommendations to an office in Carson City.

State Sen. Patricia Farley said the new office removes “barriers to simple, efficient access to medical marijuana patient cards.”

“I am impressed at the efforts the Nevada Dispensary Association and the Division have expended toward reaching the common goal of serving Nevada’s patients,” she said in the report.

When Nevada’s first dispensary opened in Starks last July there were 10,000 medical marijuana cards issued by the state. Today there are more than 18,000 people approved to use cannabis therapies in Nevada.

Joe Pollock, deputy administrator for the division, said the new office will streamline the process for obtaining medical cannabis in the state.

“We are pleased to expedite, improve and simplify this process to make the medical use of marijuana more readily accessible for patients,” he said.

End


Will ‘Big Marijuana’ Ruin Everything? Major Brookings Report Says No

“Worry about bad marijuana — not Big Marijuana,” reads the headline of a Brookings Institution report released last week. The report was written by John Hudak and Jonathan Rauch, both senior fellows in governance at Brookings.

The possibility of corporate cannabis lobbying has proven to be of concern for lawmakers and activists alike, though Hudak and Rauch take a stand against such alarmism in their latest report. Their report argues that, rather than worrying about a potential corporate marijuana takeover, lawmakers would be better served addressing consumer safety in a freshly legalized cannabis market.

According to the authors, corporatization often leads to more responsible business practices among peers. “The best regulation is the one that doesn’t need to be imposed, because reputational accountability or market pressures solved the problem first,” Hudak and Rauch wrote.

Ultimately, Hudak and Rauch compare the likely future of legal cannabis to that of alcohol — a regulatory model far displaced from the “notorious heyday” of Big Tobacco.

From the authors’ conclusions:

“The marijuana industry will remain a diverse one even as large corporations emerge. The Big Marijuana rubric is more misleading than helpful as a guide to policy because it oversimplifies and stereotypes what is in reality a continuum of business scales and structures. … Policy should concern itself with harmful practices, not with industry structure, and it should begin with a presumption of neutrality on issues of corporate size and market structure.”

The looming ‘Big Marijuana’ threat has become one of the last defensible arguments that prohibitionists rely on in their fight against cannabis law reform — these findings, however, may prove to dismantle that argument.

End


Jim McMahon Says NFL Players Should Have Access to MMJ

Jim McMahon, ex-NFL star quarterback who helped carry the Chicago Bears to victory in Superbowl XX, called for allowing NFL players to medicate using cannabis while speaking last week at The Cannabis World Congress & Business Exposition in Manhattan.

“There’s so many uses to this plant,” said McMahon. “Hundreds of thousands of people are dying from [painkillers] and there’s not one case of people dying from the hemp plant.”

McMahon is no stranger to cannabis advocacy, and has openly admitted to using the plant both during and after his illustrious football career — he’s even stated that he wishes he had used the plant more often as a safer and less-toxic painkiller option than the opiates that football players are typically prescribed by the fistful.

McMahon has said in the past that his marijuana use helped him kick an addiction that had the ex-football star taking up to 100 Percocets per month.

McMahon joins the Baltimore Raven’s ex-offensive tackle Eugene Monroe in his recent cannabis advocacy. In a widely-publicized move earlier this year, Monroe donated $80,000 to boost medical marijuana research. Monroe, who was the first active NFL player to advocate for medical cannabis, was cut from the Ravens last week and is now a free agent.

End